Viveve Medical (VIVE) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock VIVE vs. NMRD, UTRS, MOTS, DRTSW, ANZUW, ATAKW, BBLGW, HSCSW, BEATW, and LUCYWShould you be buying Viveve Medical stock or one of its competitors? The main competitors of Viveve Medical include Nemaura Medical (NMRD), Minerva Surgical (UTRS), Motus GI (MOTS), Alpha Tau Medical (DRTSW), Anzu Special Acquisition Corp I (ANZUW), Aurora Technology Acquisition (ATAKW), Bone Biologics (BBLGW), Heart Test Laboratories (HSCSW), HeartBeam (BEATW), and Innovative Eyewear (LUCYW). These companies are all part of the "medical equipment" industry. Viveve Medical vs. Its Competitors Nemaura Medical Minerva Surgical Motus GI Alpha Tau Medical Anzu Special Acquisition Corp I Aurora Technology Acquisition Bone Biologics Heart Test Laboratories HeartBeam Innovative Eyewear Nemaura Medical (NASDAQ:NMRD) and Viveve Medical (NASDAQ:VIVE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings. Does the media favor NMRD or VIVE? In the previous week, Nemaura Medical's average media sentiment score of 0.00 equaled Viveve Medical'saverage media sentiment score. Company Overall Sentiment Nemaura Medical Neutral Viveve Medical Neutral Do insiders & institutionals hold more shares of NMRD or VIVE? 4.4% of Nemaura Medical shares are owned by institutional investors. 40.4% of Nemaura Medical shares are owned by company insiders. Comparatively, 5.7% of Viveve Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is NMRD or VIVE more profitable? Company Net Margins Return on Equity Return on Assets Nemaura MedicalN/A N/A N/A Viveve Medical N/A N/A N/A Which has more risk and volatility, NMRD or VIVE? Nemaura Medical has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Viveve Medical has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Which has better earnings and valuation, NMRD or VIVE? Viveve Medical has higher revenue and earnings than Nemaura Medical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNemaura Medical$3.02K0.00-$14.14M-$0.39N/AViveve Medical$6.83M0.00N/AN/AN/A SummaryNemaura Medical beats Viveve Medical on 3 of the 4 factors compared between the two stocks. Get Viveve Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVE vs. The Competition Export to ExcelMetricViveve MedicalElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$33.76M$5.50B$9.72BDividend YieldN/AN/A4.59%4.12%P/E RatioN/A3.1330.0524.70Price / SalesN/A198.64456.53100.55Price / CashN/A41.3624.8428.01Price / BookN/A1.838.525.76Net IncomeN/A-$2.66M$3.27B$267.05M Viveve Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVEViveve MedicalN/AN/AN/AN/A$1K$6.83M0.0070NMRDNemaura Medical1.15 of 5 starsN/AN/AN/A$4K$3.02K0.0040UTRSMinerva SurgicalN/AN/AN/AN/A$1K$51.69M0.00160MOTSMotus GI0.0734 of 5 stars$0.00flatN/A-99.6%$1K$319K0.0030DRTSWAlpha Tau MedicalN/A$0.26+5.2%N/A+33.5%$0.00N/A0.0080Gap UpANZUWAnzu Special Acquisition Corp IN/A$0.05+3.5%N/AN/A$0.00N/A0.002Gap UpATAKWAurora Technology AcquisitionN/A$0.02-18.0%N/A-62.8%$0.00N/A0.00N/AGap UpBBLGWBone BiologicsN/A$15.00+11.1%N/AN/A$0.00N/A0.002Gap UpHSCSWHeart Test LaboratoriesN/A$0.18+48.8%N/A+215.2%$0.00$4.35K0.0010Gap UpHigh Trading VolumeBEATWHeartBeamN/A$0.31+10.7%N/A-16.7%$0.00N/A0.005Gap UpLUCYWInnovative EyewearN/A$0.11+24.3%N/A+93.0%$0.00$1.71M0.009Gap Up Related Companies and Tools Related Companies Nemaura Medical Competitors Minerva Surgical Competitors Motus GI Competitors Alpha Tau Medical Competitors Anzu Special Acquisition Corp I Competitors Aurora Technology Acquisition Competitors Bone Biologics Competitors Heart Test Laboratories Competitors HeartBeam Competitors Innovative Eyewear Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVE) was last updated on 8/10/2025 by MarketBeat.com Staff From Our Partners#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viveve Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viveve Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
